+44 20 8123 2220
info@marketpublishers.com

World Multiple Myeloma Drug Treatment Market 2012-2022

https://marketpublishers.com/r/W677B1E0129EN.html
Date: September 2012
Pages: 136
Price: US$ 2,635.00 (Single User License)
ID: W677B1E0129EN

Abstracts

Your guide to trends and revenue prospects for treating multiple myeloma

See what the future holds for products to treat multiple myeloma. Visiongain's updated report gives you revenue predictions to 2022. There you find data, trends, opportunities and commercial prospects.

Our study lets you assess forecasted sales at overall world market, product and national level. Those analyses help you see the future of that industry and market.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, news, research and development (R&D) and business outlooks. You receive 42 tables, 39 charts and a research interview.

We show where growth can occur. Our work lets you investigate the most lucrative areas, helping you stay ahead in knowledge.

The following sections highlight what you discover in the report.

Our work shows you prospects for the world market and leading products

In addition to analysis of the overall world market, our study shows you revenue forecasting of five products to 2022:

Revlimid

Thalomid

+44 20 8123 2220
info@marketpublishers.com

Actimid

Velcade

Kyprolis.

Also, you see how five late-stage drug candidates - Elotuzumab, MLN9708, Perifosine, Faridak and Aplidin - can perform to 2022. See potential revenues. Our investigation shows you business research and analyses with individual sales forecasts and discussions.

Our work also breaks overall world revenue into leading countries.

National market prospects - which countries will have the highest growth?

There are many commercial opportunities in developed and developing countries, our study shows. You discover individual revenue forecasts to 2022 for eleven national markets:

US

Japan

Germany, France, UK, Italy and Spain (EU5)

Brazil, Russia, India and China (BRIC nations).

There will be high revenue growth in the established pharma markets, but also opportunities in developing countries, especially India and China. Also, product launches from 2012 onwards will benefit leading national markets. Our report shows opportunities for new drugs.

Research and development - you see trends and prospects for technologies

What about the R&D pipeline for that area of oncology? Our work shows you developmental trends by phase. You investigate developments including these:

+44 20 8123 2220
info@marketpublishers.com

Monoclonal antibodies (mAbs) and other biologics

Small-molecule products

Protein kinase inhibition

HDAC inhibition

Inhibition of protein synthesis and induction of apoptosis.

Beyond proteasome inhibitors and immunomodulators, promising candidates include HDAC inhibitors, kinase inhibitors and orally-bioavailable second-generation proteasome inhibitors.

Discover how technology can change the treatment of multiple myeloma, finding progress and outlooks. Our investigation shows activities of companies treating that blood cancer.

Leading companies and revenue prospects

What will happen next? The pharmaceutical industry will improve treatments for multiple myeloma and increase revenues from 2012 to 2022. The R&D pipeline is strong.

Overall world revenue for that market area will reach $9.9bn in 2015, our report forecasts. Incidence and prevalence of multiple myeloma worldwide will stimulate demand to 2022.

Also, biological drugs will transform the market, improving treatment of blood cancer, including neoplasm in bone marrow.

In our study you find discussions and analyses of Celgene, Johnson & Johnson, Novartis, Onyx and other developers and manufacturers. This decade, many opportunities will arise for companies treating cancers.

Nine ways World Multiple Myeloma Drug Treatment Market 2012-2022 helps you

In particular, then, our report gives you the following knowledge on the topic:

+44 20 8123 2220
info@marketpublishers.com

Forecasted revenue to 2022 for the overall world market - find the industry's prospects

Potential revenues of 10 products to 2022 - analyse crucial developments

Market forecasting to 2022 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see leading national prospects

Assessment of companies - find discussions of activities, products and outlooks

Review of R&D pipelines - investigate developmental trends and progress

Opinions on the sector - discover views, including a research interview

Investigation of competition and opportunities influencing sales

Discussions of what stimulates and restrains the industry and market

Prospects for established companies and those seeking to launch products.

That work gives you quantitative and qualitative analyses with independent predictions. You receive information found only in our study.

There you find business intelligence to help you understand the future of the industry and market. You see where prospects are lucrative and growth is likely.

Discover how our work could benefit your research and analyses, saving you time too.

By ordering now you discover prospects for products to treat multiple myeloma

Visiongain's study is for everybody needing commercial analyses for the treatment of multiple myeloma. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

6. THE MULTIPLE MYELOMA R&D PIPELINE: SMALL-MOLECULE PRODUCTS, 2012

+44 20 8123 2220
info@marketpublishers.com

7. THE MULTIPLE MYELOMA R&D PIPELINE: BIOLOGICS, 2012

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

10. CONCLUSIONS

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

COMPANIES LISTED

AB Science
Abbott
Abiogen
Acceleron
AdaptImmune
Aeterna Zentaris
Allos Therapeutics
Alza
Amgen
Ariad Pharmaceuticals
Arkansas Cancer Research Center
Arno Therapeutics
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Bayer
Ben Venue Laboratories
Biogen Idec
Biotest Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Broad Institute

+44 20 8123 2220
info@marketpublishers.com

Calistoga Pharmaceuticals
Callisto Pharmaceuticals
Cancer Research UK
Celgene
Cell Genesys
Cephalon
Chiron
Chugai Pharmaceuticals
Columbia University
CombinatoRx
Compugen
Constellation Pharmaceuticals
Curis
CyDex
Cytokinetics
Cytopia
CytRx Corporation
Eli Lilly
EntreMed
Epizyme
European Medicines Agency (EMEA/EMA)
Facet Biotech
Food and Drug Administration (US FDA)
Genentech
Genmab
Genzyme
Geron
GlaxoSmithKline
Handok
Human Genome Sciences
Immune System Therapeutics
ImmunoGen
Immunomedics
Incyte Corporation
Infinity Pharmaceuticals
Intellikine
Italfarmaco
Jakafi
Janssen

+44 20 8123 2220
info@marketpublishers.com

Johnson & Johnson
Karyopharm Therapeutics
Kayaku Zentaris
Keryx Biopharmaceuticals
Kirin Pharma
Kosan Biosciences
Kyowa Hakko Kirin
Lipomed
MacroGenics
Mayo Clinic
MD Anderson Cancer Center
Merck & Co.
MethylGene
Micromet
Millennium Pharmaceuticals
MorphoSys
Multiple Myeloma Research Consortium (MMRC)
Multiple Myeloma Research Foundation
Natco Pharma
National Cancer Institute
National Institute for Health and Clinical Excellence (NICE)
Nereus Pharmaceuticals
Nippon Shinyaku
Novartis
Novo Nordisk
Oncolytics
Oncovir
Ono
Onyx Pharmaceuticals
PDL BioPharma
Pfizer
Pharmacia
Pharmacyclics
PharmaMar
Pierre Fabre
Prochon Biotech
Prometheus Labs
Protein Design
Regeneron

+44 20 8123 2220
info@marketpublishers.com

Roche
Rockefeller University
Salmedix
Schering-Plough
Scios
Seattle Genetics
Senesco Technologies
Sidney Kimmel CCC
Sloan Kettering
Sugen
Sun Pharma
Sydney Kimmel CCC
Synta Pharmaceuticals
Takeda
Targa Therapeutics
Teva Pharmaceutical Industries
Threshold Pharmaceuticals
Translational Genomics Research Institute
UAMS
University of Arkansas
University of Illinois
Vertex
Weill Cornell Medical College
World Health Organization (WHO)
Xencor
Zeltia
Zenyaku Kogyo

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: World Multiple Myeloma Drug Treatment Market 2012-2022
Product link: https://marketpublishers.com/r/W677B1E0129EN.html
Price: US$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/W677B1E0129EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970